Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of AstraZeneca PLC (NASDAQ:AZN)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of AstraZeneca PLC (NASDAQ:AZN). In a filing disclosed on November 18th, the Representative disclosed that they had bought between $1,001 and $15,000 in AstraZeneca stock on October 21st. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of CommVault Systems (NASDAQ:CVLT) on 11/3/2025.
• Sold $1,001 – $15,000 in shares of The Descartes Systems Group (NASDAQ:DSGX) on 11/3/2025.
• Purchased $1,001 – $15,000 in shares of Cohen & Steers (NYSE:CNS) on 10/30/2025.
• Purchased $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 10/30/2025.
• Sold $1,001 – $15,000 in shares of UFP Industries (NASDAQ:UFPI) on 10/30/2025.
• Purchased $1,001 – $15,000 in shares of Enerpac Tool Group (NYSE:EPAC) on 10/30/2025.
• Sold $1,001 – $15,000 in shares of Sterling Infrastructure (NASDAQ:STRL) on 10/30/2025.
• Purchased $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 10/21/2025.
• Purchased $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 10/21/2025.
• Purchased $1,001 – $15,000 in shares of Iberdrola (OTCMKTS:IBDSF) on 10/21/2025.

AstraZeneca Stock Performance

Shares of AZN traded down $0.31 during trading hours on Thursday, reaching $88.68. 5,862,630 shares of the company traded hands, compared to its average volume of 5,148,094. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55. The business has a fifty day moving average price of $82.62 and a 200-day moving average price of $76.57. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $90.27. The stock has a market capitalization of $275.03 billion, a P/E ratio of 33.34, a P/E/G ratio of 1.52 and a beta of 0.34.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Thursday, November 6th. The company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. The company had revenue of $15.19 billion during the quarter, compared to analysts’ expectations of $14.75 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The firm’s revenue was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.08 EPS. Equities analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Institutional Trading of AstraZeneca

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Primecap Management Co. CA boosted its stake in shares of AstraZeneca by 1.3% during the 2nd quarter. Primecap Management Co. CA now owns 41,200,091 shares of the company’s stock worth $2,879,062,000 after acquiring an additional 538,606 shares in the last quarter. Bank of America Corp DE raised its holdings in AstraZeneca by 4.7% in the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock worth $2,503,614,000 after purchasing an additional 1,461,786 shares during the period. Franklin Resources Inc. boosted its position in AstraZeneca by 0.9% during the second quarter. Franklin Resources Inc. now owns 21,298,394 shares of the company’s stock worth $1,488,332,000 after purchasing an additional 196,401 shares in the last quarter. Fisher Asset Management LLC grew its holdings in AstraZeneca by 2.3% in the third quarter. Fisher Asset Management LLC now owns 21,162,724 shares of the company’s stock valued at $1,623,604,000 after purchasing an additional 466,745 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in shares of AstraZeneca by 30.9% in the first quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company’s stock valued at $1,003,124,000 after buying an additional 3,224,251 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Ratings Changes

AZN has been the topic of a number of recent research reports. Jefferies Financial Group initiated coverage on AstraZeneca in a research report on Monday, October 27th. They issued a “buy” rating on the stock. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, AstraZeneca currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.00.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.